Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

BACKGROUND: Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO‐7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, Nobuyuki, Uchino, Junji, Yokoyama, Takuma, Naito, Tateaki, Kondo, Masashi, Yamada, Kouzo, Kitajima, Hiromoto, Yoshimori, Kozo, Sato, Kazuhiro, Saito, Hiroshi, Aoe, Keisuke, Tsuji, Tetsuya, Takiguchi, Yuichi, Takayama, Koichi, Komura, Naoyuki, Takiguchi, Toru, Eguchi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814824/
https://www.ncbi.nlm.nih.gov/pubmed/29205286
http://dx.doi.org/10.1002/cncr.31128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814824/
https://www.ncbi.nlm.nih.gov/pubmed/29205286
http://dx.doi.org/10.1002/cncr.31128

Ejemplares similares